Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07723118
PHASE1

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

Sponsor: Mirati Therapeutics Inc.

View on ClinicalTrials.gov

Summary

The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent

Official title: A Phase 1, Single-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-08-05

Completion Date

2026-09-14

Last Updated

2026-09-28

Healthy Volunteers

Yes

Interventions

DRUG

Adagrasib

Specified dose on specified days

Locations (1)

Local Institution - 0001

Anaheim, California, United States